Solid Biosciences
SLDB
74 hedge funds and large institutions have $128M invested in Solid Biosciences in 2019 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 22 increasing their positions, 14 reducing their positions, and 20 closing their positions.
169% more call options, than puts
Call options by funds: $3.41M | Put options by funds: $1.27M
57% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 14
10% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 20
0.78% more ownership
Funds ownership: 3.22% → 4% (+0.78%)
0% more funds holding
Funds holding: 74 → 74 (0)
19% less capital invested
Capital invested by funds: $157M → $128M (-$29.4M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$28.6M |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
+$6.01M |
| 3 |
Millennium Management
New York
|
+$2.54M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$2.18M |
| 5 |
BlackRock
New York
|
+$949K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$2.88M |
| 2 |
EU
Emory University
Atlanta,
Georgia
|
-$2.75M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$2.39M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$2.3M |
| 5 |
TCS
Texas Children's
Houston,
Texas
|
-$1.29M |
SLDB Hedge Fund Activity: Q2 2019 in Review
74 of the 4,604 institutional investors tracked by Wall St. Rank reported a position in Solid Biosciences (SLDB) for Q2 2019, worth a combined $128M — down 19% from $157M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new SLDB positions and 20 closed out — a net gain of 2 holders — while 22 added to existing stakes and 14 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $28.6M. The largest seller was Barclays, cutting an estimated $2.88M.
- 74 institutional investors held Solid Biosciences (SLDB) as of Q2 2019, unchanged from Q1 2019.
- Funds reported $128M of Solid Biosciences stock for Q2 2019, down 19% quarter-over-quarter.
- 22 funds opened new Solid Biosciences positions in Q2 2019 and 20 closed out, a net change of +2 holders.
- The largest Solid Biosciences buyer in Q2 2019 was Perceptive Advisors, an estimated $28.6M added.
- The largest Solid Biosciences seller in Q2 2019 was Barclays, an estimated $2.88M sold.
Based on aggregated 13F filings for Q2 2019.